CYCN - Cyclerion Therapeutics Inc
Previous close
3.15
0 0%
Share volume: 292
Last Updated: Thu 29 Aug 2024 06:00:00 AM CEST
Research and Development in Biotechnology (except Nanobiotechnology):
0.21%
PREVIOUS CLOSE
CHG
CHG%
$3.15
0.00
0.00%
View ratios
| Fiscal Date | 2022-03-31 | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | |
|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q1 2022 | Q2 2022 | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | |
| Report Date | 2022-05-04 | 2022-08-09 | 2022-11-03 | 2023-03-22 | 2023-05-12 | 2023-07-28 | 2023-11-13 | |
| Assets | ||||||||
| Total Assets | 46.525 M | 35.213 M | 25.053 M | 18.079 M | 11.456 M | 10.097 M | 15.214 M | |
| Current Assets | 42.836 M | 31.679 M | 21.656 M | 14.820 M | 8.335 M | 7.113 M | 9.864 M | |
| Inventories | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Other Current Assets | 1.484 M | 1.129 M | 1.024 M | 1.342 M | 1.070 M | 1.472 M | 756.000 K | |
| Short Term Investments | 1.484 M | 1.129 M | 1.024 M | 1.342 M | 1.070 M | 1.472 M | 756.000 K | |
| Total Receivables | 227.000 K | 227.000 K | 227.000 K | 96.000 K | 96.000 K | 0.000 | 0.000 | |
| Current Cash | 41.125 M | 30.323 M | 20.405 M | 13.382 M | 7.169 M | 5.641 M | 9.108 M | |
| Total Non-current Assets | 3.689 M | 3.534 M | 3.397 M | 3.259 M | 3.121 M | 2.984 M | 5.350 M | |
| Property Plant Equipment | 17.000 K | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Other Assets | 3.672 M | 3.534 M | 3.397 M | 3.259 M | 3.121 M | 2.984 M | 0.000 | |
| Intangible Assets | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Goodwill | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Liabilities and shareholders’ equity | ||||||||
| Total Liabilities and shareholders’ equity | 46.525 M | 35.213 M | 25.053 M | 18.079 M | 11.456 M | 10.097 M | 15.214 M | |
| Total liabilities | 9.491 M | 9.852 M | 8.529 M | 7.627 M | 7.531 M | 4.947 M | 2.341 M | |
| Total current liabilities | 9.491 M | 9.852 M | 8.529 M | 7.627 M | 7.531 M | 4.947 M | 2.341 M | |
| Accounts Payable | 2.519 M | 2.767 M | 1.645 M | 2.970 M | 3.925 M | 1.864 M | 814.000 K | |
| Other liabilities | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Current long term debt | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Long term debt | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Other liabilities | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Minority interest | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Total Shareholder equity | 37.034 M | 25.361 M | 16.524 M | 10.452 M | 3.925 M | 5.150 M | 12.873 M | |
| Common stock | 2.171 M | 2.173 M | 2.174 M | 2.175 M | 2.176 M | 2.282 M | 2.435 M | |
| Retained earnings | -228.054 M | -241.442 M | -251.938 M | -259.154 M | -266.108 M | -270.289 M | -262.723 M |